MedTrace Logo

GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19)

NCT04590547 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2025-04-11

Study results available
· View outcomes & findings →

Summary

This clinical trial will evaluate the safety, tolerability and efficacy of GLS-1027 in the prevention of severe pneumonitis caused by SARS-CoV-2 infection

Conditions

Interventions

DRUG

GLS-1027

GLS-1027 is an oral medication with high bioavailability that has IL-6 and IL-1β inhibitory activity.

DRUG

Placebo

Placebo looks like GLS-1027

Sponsors & Collaborators

  • GeneOne Life Science, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-07
Primary Completion
2022-08-14
Completion
2023-07-24
FDA Drug
Yes

Countries

  • United States
  • Bulgaria
  • North Macedonia
  • Puerto Rico
  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04590547 on ClinicalTrials.gov